New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and organisations with an Australian presence will be able to register a name of their choosing directly...

New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and organisations with an Australian presence will be able to register a name of their choosing directly...
Originally published in the IAM Saturday Opinion on 11 September 2021. Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an artificial intelligence (AI)...
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with reference trastuzumab in early or locally advanced HER2 positive breast cancer. Samsung Bioepis...
02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021. 06 Sep 21 | IN | Hetero announced that it...
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and support has actually been raised by Australia’s 2012 ‘Raising the Bar’ law reforms. This is the second...
Pearce IP is proud to announce that Special Counsel, Patent Attorney and Trade Mark Attorney, Jennifer Enmon PhD, JD has been recognised by Lawyer Monthly (Women in Law Awards 2021) as Patents Lawyer of the Year for...
Pearce IP is proud to announce that Pearce IP’s Founding Principal and Executive Lawyer, Patent and Trade Mark Attorney, Naomi Pearce, has once again been recognised as a World Leading Patent Strategist by IAM Strategy...
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit wire fraud exceeding $101 million in the US District Court for the Northern District of California. The...
Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an artificial intelligence (AI) system, DABUS, can be an inventor of a patent. Reaction to this...
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F inhibitor indicated for the treatment of adults with moderate to severe plaque psoriasis. 25 Aug 21 |...
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to NEULASTA® (pegfilgrastim) in an IPR challenge brought by Pfizer and Hospira. The PTAB declined to...
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when a patent covers two pharmaceutical substances of the patentee, a patent term extension (PTE)...
Boutique specialist firm Pearce IP is delighted to announce that Senior Associate, Belinda Hartmann PhD commenced with Pearce IP last week. Belinda is a Trans-Tasman patent attorney with biological sciences expertise,...
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar trastuzumab) and pertuzumab administered as an admixture in a single infusion bag is consistent...
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as alternatives to Avastin® (bevacizumab) in the...
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar development and manufacturing. 28 Jul 21 | Prestige BioPharma announced that HD201 (proposed trastuzumab...
The Australian Federal Court in Thaler v Commissioner of Patents [2021] FCA 879 (30 July 2021) has determined that an artificial intelligence (AI) system, DABUS, can be an inventor of a patent. However, the Court also...
Pearce IP is proud to announce that Principal and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been listed by WIPR Diversity as one of the world’s top 100 Influential Women in IP for 2021....
19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of HLX04-O (proposed bevacizumab biosimilar) in the treatment of wet age-related macular degeneration. 19...
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which measures adalimumab levels in blood. The test is able to return a result within 10 minutes using whole...
05 Jul 21 | Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar darbepoetin alfa). Under the agreement, Chong Kun Dang will receive a down payment and milestone...
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe, significant differences remain. This means that patent practitioners operating in one jurisdiction need to...
27 Jun 21 | CN | Innovent Biologics announced China’s National Medical Products Administration has approved its supplemental New Drug Application for Tyvyt® (sintilimab) in combination with Byvasda® (biosimilar...
Pearce IP recently reported on the Full Court of the Federal Court decision in Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101, which confirmed that a method of detecting cell-free foetal DNA (cffDNA) in...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.